[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"arterial-hypertension\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:arterial-hypertension":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,17,0,[8,59,99,120,150,181,208,235,255,277,302,331,357,385,415,445,473],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":37,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":58},"100506981","prevalence-incidence-and-risk-signature-of-chronic-kidney-disease-in-sub-saharan-africa-100506981",false,"NCT05881447","Prevalence, Incidence and Risk Signature of Chronic Kidney Disease in Sub-Saharan Africa","Prevalence, Incidence and Risk Signature of Chronic Kidney Disease in a Primary Care Setting in Semirural Sub-Saharan Africa","RenalTWO","Inclusion Criteria:\n\nall adult patients (≥18 years) attending the outpatients department of the Bagamoyo district hospital (BDH) or the associated Fukayosi and Yombo dispensary\n\nExclusion Criteria:\n\n* \\\u003C18 years of age\n* not living in the BDH catchment area\n* not of African decent\n* not willing to come back for follow-up visits","ALL","18 Years","99 Years",{"count":21,"type":22},1200,"ESTIMATED","OBSERVATIONAL","Chronic kidney disease (CKD) is associated with increased cardiovascular morbidity and mortality. The prevalence of CKD is increasing worldwide and is assumed to also dramatically increase in Sub-Saharan Africa (SSA). Key shortcomings of available data on CKD in SSA are as follows: (i) Available data are based on single measurements and, therefore, cannot distinguish between harmless transient deterioration in kidney function and chronic kidney damage; (ii) Accurate information regarding renal protein loss, an important and early marker of kidney disease, is lacking; (iii) Cardiovascular risk factors for CKD, such as obesity, hypertension and diabetes, are often not searched for. Likewise non-classic potential risk factors, such as endemic infectious diseases, socioeconomic status and lifestyle have not been consistently recorded; (iv) Information to interrogate linked interaction over time between risk factors and development of CKD is unavailable. With this project, situated in a region representative of semi-rural SSA, we aim to fill this knowledge gap and (i) establish guideline conform prevalence data of CKD and its major cardiovascular risk factors, as well as (ii) prospectively define the incidence of cardiovascular- and non-classic risk factors of CKD. The data from (i) and (ii) is used to develop predictive models. A prospective cohort of 1200 individuals in a primary care facility will serve as study population. The population is representing a society in transition from rural to more urban lifestyle. In the pilot study, participants will be followed for one years and undergo the clinical and biomedical testing required to capture CKD and its classic and non-classic risk factors over time.",[26,27,28,29,30,31,32,33,34,35,36],"Chronic Kidney Diseases","Type 2 Diabetes Mellitus","Arterial Hypertension","Obesity","Cardiovascular Diseases","HIV Infections","Anemia","Underweight","Infections","Albuminuria","Dyslipidemias",[38,39,40,32,41,42,43,44,45],"CKD","Risk factors","Cardiovascular disease","Point of care diagnostics","Albumin creatinine ration (ACR)","Estimated glomerular filtration rate (eGFR)","Kidney Disease: Improving Global Outcomes (KDIGO)","HbA1c","RECRUITING","2026-04-23",{"date":49,"type":50},"2026-04-29","ACTUAL",{"date":52,"type":50},"2023-06-21",{"date":54,"type":22},"2026-12-31",{"name":56,"class":57},"Swiss Tropical & Public Health Institute","OTHER",1,{"id":60,"slug":61,"hasResults":11,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":4,"eligibilityCriteria":65,"healthyVolunteers":66,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":67,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":69,"conditions":70,"keywords":78,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":4},"100623450","screening-for-cardiac-and-cardiac-associated-pathology-using-single-channel-electrocardiogram-100623450","NCT07396792","Screening for Cardiac and Cardiac-associated Pathology Using Single-channel Electrocardiogram","Screening for Cardiac and Cardiac-associated Pathology Using Single-channel Electrocardiogram Analyzed With Machine Learning Models","Inclusion Criteria:\n\n1. The presence of written informed consent of the patient to participate in the study\n2. Availability of examination data allowing for the verification or exclusion of cardiac and cardiac-associated pathology\n3. Age 18 years old and older\n\nNon-inclusion criteria:\n\n1. Patients with an implanted permanent pacemaker;\n2. ECG changes that prevent spectral analysis;\n3. Conditions that may impair the quality of the ECG recording (Parkinson's disease, essential tremor, etc.);\n4. Conditions that make ECG recording in lead I impossible (congenital anomalies of the upper limbs, traumatic amputation of the upper limbs).\n5. Lack of written informed consent from the patient to participate in the study.\n\nExclusion Criteria:\n\n1. Poor quality of the ECG recording on a single-channel ECG monitor\n2. Insufficient examination data to verify or exclude cardiac or cardiac-associated pathology;\n3. Patient's unwillingness to continue participating in the study for any reason.",true,{"count":68,"type":22},4000,"It is a prospective, controlled, single-center, observational, non-randomized study. The study is planned to include at least 4000 patients 18 years old and older in the training sample and 1000 patients over 18 years old in the test sample (the total number of patients is at least 5000 people). Patients will be included in the study if they have undergone a full examination (laboratory, clinical and instrumental), allowing for the verification or exclusion of cardiac and cardiac-associated pathology in accordance with current recommendations. During the course of the study, the authors of the work do not interfere with the above-mentioned scope of the examination, which is carried out on patients in accordance with clinical guidelines. All patients included in the study will undergo ECG recording in standard lead I for 1 minute twice, followed by spectral analysis of the obtained data, which will be stored at the remote monitoring center of Sechenov University without being linked to the personal data of patients. A spectral analysis of the electrocardiogram will be performed using a continuous wavelet transform. The result of this study will be the identification of ECG parameters that will correlate with cardiac and cardiac-associated pathology",[28,71,72,73,74,75,76,77],"Heart Rhythm Disorders","Valvular Heart Diseases","Heart Failure","Diabetes Mellitus","Chronic Kidney Disease (Stage 3-4)","Metabolic Syndrome","Coronary Artery Disease",[79,80,81,82,83,84,85,86,87,88],"Screening","Electrocardiogramm","single-channel electrocardiogram","machine learning models","Coronary artery disease","diabetes mellitus","metabolic syndrome","anemia","hypercholesterolemia","arterial hypertension","NOT_YET_RECRUITING","2026-04-13",{"date":92,"type":50},"2026-04-16",{"date":94,"type":22},"2026-04-01",{"date":96,"type":22},"2028-05-13",{"name":98,"class":57},"I.M. Sechenov First Moscow State Medical University",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":106,"targetDuration":108,"studyType":23,"phases":4,"briefSummary":109,"conditions":110,"keywords":4,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":5},"100374828","registry-of-arterial-hypertension-100374828","NCT04160533","Registry of Arterial Hypertension","Registry of Arterial Hypertension: \"Study of Modern Phenotypes of Arterial Hypertension, Including Secondary Forms, in Order to Create Personalized Methods of Treatment\"","Inclusion Criteria: The diagnosis of arterial hypertension -\n\nExclusion Criteria: No diagnosis of arterial hypertension\n\n\\-",{"count":107,"type":22},10400,"1 Day","The problem of the quality of primary health care medical system for patients with arterial hypertension is acute for the investigator's country, as these diseases are the most common and cause the high mortality of the population.\n\nThe concept of \"quality of primary health care medical system\" includes its timeliness, accessibility and provision of medical care to the patient at the modern level, which is determined by the degree of performance by doctors of medical and diagnostic measures corresponding current clinical recommendations.\n\nThe system of cardiovascular desease registries, established in the Federal State Clinical Hospital of the Russian Federation Ministry of Public Health with the automated analysis of data on examination and treatment, in comparison with clinical Recommendations. It makes possibility to identify shortcomings and develop approaches to improving the provision of medical care to patients in real clinical practice.\n\nComparative analysis of the quality of examination and treatment in different samples of patients with cardiovascular desease, observed in 2018-2020, compared with results of previous years will identify ptrends in the provision of medical care to patients with cardiovascular desease.",[28],"2026-04-08",{"date":90,"type":50},{"date":114,"type":50},"2018-06-01",{"date":116,"type":22},"2026-12",{"name":118,"class":119},"National Medical Research Center for Cardiology, Ministry of Health of Russian Federation","OTHER_GOV",{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":4,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":127,"enrollmentInfo":128,"targetDuration":4,"studyType":130,"phases":131,"briefSummary":133,"conditions":134,"keywords":138,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":148,"locationsCount":58},"100529089","early-phase-1-effect-of-nitrate-supplementation-on-blood-pressure-and-microvascular-function-of-resistant-hypertensive-patients-100529089","NCT06169241","Effect of Nitrate Supplementation on Blood Pressure and Microvascular Function of Resistant Hypertensive Patients","Effect of Nitrate Supplementation on Blood Pressure and Systemic Microvascular Function of Resistant Hypertensive Patients","Inclusion Criteria:\n\n* Resistant hypertension, with a diagnosis described in the medical record, without changing medications or increasing doses in the last 30 days.\n\nExclusion Criteria:\n\n* neoplasms\n* heart failure\n* use of medications with nitrate in their formula\n* patients undergoing renal denervation","75 Years",{"count":129,"type":22},50,"INTERVENTIONAL",[132],"EARLY_PHASE1","Arterial hypertension (AH) has been identified as an important public health problem and considered a new epidemic with high mortality and morbidity. High blood pressure (BP) levels increase the chances of coronary artery disease (CAD), heart failure (HF), stroke, chronic renal failure (CRF) and death. Beetroot powder may be an easier way to increase the availability of nitric oxide and consequently vasodilation in these patients. However, studies are needed to evaluate its benefits in patients with AH.",[28,135,136,137],"Resistant Hypertension","Microvascular Function","Nitrate Supplementation",[139,140,141,142],"microcirculation","capillary density","microvascular reactivity","systemic resistant hypertension","2026-04-07",{"date":90,"type":50},{"date":146,"type":50},"2023-11-01",{"date":116,"type":22},{"name":149,"class":119},"National Institute of Cardiology, Laranjeiras, Brazil",{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":156,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":158,"targetDuration":160,"studyType":23,"phases":4,"briefSummary":161,"conditions":162,"keywords":167,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":58},"100608847","observational-study-for-the-characterisation-of-patients-affected-by-any-type-of-diabetes-and-endocrine-disorders-100608847","NCT07206875","Observational Study for the Characterisation of Patients Affected by Any Type of Diabetes and Endocrine Disorders","Retrospective and Prospective Observational Registry for the Characterisation of Patients Affected by Any Type of Diabetes and Endocrine-metabolic Disorders","DiabRegistry","Inclusion Criteria:\n\n* Age ≥18 years\n* Outpatient Diabetes Unit patient\n* Ability to give informed consent\n\nDiagnosis of at least one of the following:\n\n* Metabolic disease, defined as BMI ≥25 Kg\u002Fm2\n* Type 1 or type 2 diabetes mellitus\n* Gestational diabetes\n* Monogenic diabetes (MODY)\n* Other types of diabetes or dysglycemia\n* Dyslipidemia\n* Arterial hypertension\n* Steatosis liver disease (SLD)\n\nExclusion Criteria:\n\n* Age \\\u003C18 years\n* Deny participation at the study\n* Recruitment in an interventional protocol\n* Patients with missing significant data",{"count":159,"type":22},10000,"10 Years","The main objective of this retrospective and prospective observational register is to identify anthropometric, clinical, laboratory and\u002For instrumental markers of disease severity and activity in patients suffering from diabetes, endocrine-metabolic disorders, rare diseases in order to improve their diagnosis, monitoring and treatment processes. The Registry is monocentric, observational prospective and retrospective. No additional procedures to those of normal clinical practice are planned, and neither diagnostic approaches nor experimental drugs\u002Fprescriptions will be applied. The data under study (demographic, anthropometric, clinical and care characteristics) will be collected as part of outpatient visits of the Diabetes Outpatient Clinic or admission to Diabetes Day Hospital.\n\nIn case of outpatients, the observation will start at the diagnosis or during the first outpatient visit and will end with the last outpatient visit performed within the total time foreseen for the duration of the study.\n\nThe study will start once the regulatory authorizations are completed, and is expected to last at least 10 years with the possibility of extension",[163,164,28,165,166],"Diabetes","Metabolic Disorders","Dyslipidemia","Liver Disease (Alcoholic or Not)",[168,169,170,171],"diebetes","metabolic disorders","endocrine disorders","observational study","2025-10-01",{"date":174,"type":50},"2025-10-03",{"date":176,"type":22},"2025-11",{"date":178,"type":22},"2035-11",{"name":180,"class":57},"IRCCS San Raffaele",{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":185,"acronym":186,"eligibilityCriteria":187,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":188,"enrollmentInfo":189,"targetDuration":4,"studyType":130,"phases":191,"briefSummary":193,"conditions":194,"keywords":4,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":58},"100601766","renal-denervation-after-stroke-reds-study---a-randomized-clinical-trial-of-renal-denervation-in-the-subacute-phase-of-stroke-100601766","NCT07114757","REnal Denervation After Stroke (REDs) Study - A Randomized Clinical Trial of Renal Denervation in the Subacute Phase of Stroke","REDs","Inclusion Criteria:\n\n\\- We will enroll patients (at least 18 years of age and younger than 85 years old) with subacute stroke (thus occurring 7-45 days before screening), admitted to hospital, with persistently high systolic PB (≥140 mm Hg computed as the mean of 3 repeated measurements taken within 5 minutes between 8.00am and 8.30 am on 2 consecutive days, thus totaling 6 measurements), or a non-dipper profile at ambulatory BP monitoring, despite therapy with ≥2 anti-hypertensive drugs at maximum tolerated dose. Patients should be medically stable with no severe complications such as infections, or worsening of neurological status that would require immediate and intensive medical or surgical intervention.\n\nExclusion Criteria:\n\n* ⦁ Patients with cerebral bleeding due to arteriovenous malformation or intracranial aneurysm\n\n  * Hemodynamic instability\n  * Comorbidity with life expectancy ≤ 1 year\n  * Renal artery anatomy, which prevents the procedure\n  * Reno vascular disease\n  * Vascular occlusion, which prevents the procedure\n  * Secondary hypertension\n  * Subject has known hypersensitivity or contraindication to any of the study drugs\n  * The subject is currently participating in another investigational drug or device clinical study\n  * Pregnancy or nursing\n  * Presence of other anatomic or comorbid conditions or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements or impact the scientific soundness of the clinical investigation results","84 Years",{"count":190,"type":22},108,[192],"NA","The REnal Denervation after stroke (REDs) study is a national, multicenter, investigator-initiated randomized controlled clinical trial designed to assess the efficacy of catheter-based renal denervation (RDN) performed in the subacute phase of stroke among patients with drug-resistant hypertension. Conducted across 15 Italian centers, this pragmatic trial adopts a parallel-group design with participants randomized in a 1:1 ratio to receive either RDN using the Symplicity Spyral system or standard care. Randomization will occur via a secure online platform, and the intervention will be performed within 24 hours post-randomization, adhering to a standardized procedural protocol.\n\nThe trial targets adult patients aged 18 to 84 years who have experienced a stroke 7 to 45 days prior to enrollment and present with persistent systolic hypertension (≥140 mmHg) or a non-dipping profile on ambulatory blood pressure monitoring, despite the use of at least two antihypertensive medications at maximum tolerated doses. Following informed consent and verification of eligibility, enrolled patients will undergo baseline assessments including physical examination, laboratory testing, ECG, stroke severity and disability scoring, and quality of life evaluation.\n\nThe total duration of the REDs study is 48 months, encompassing a 24-month enrollment window and a 24-month follow-up period. Study endpoints, including 24-hour ambulatory blood pressure and secondary clinical and functional outcomes, will be evaluated at 3, 6, 9, 12, and 24 months following the intervention. These follow-up assessments will be conducted through hospital visits or teleconsultations as appropriate.\n\nThe primary efficacy endpoint is the change in mean 24-hour systolic blood pressure 12 months after randomization. Secondary endpoints include diastolic and mean arterial pressure, antihypertensive medication burden, time to blood pressure control, functional neurological scores (NIHSS, mRS), quality of life metrics, and stroke recurrence. Data collection will be managed via an electronic case report form (eCRF), and adverse events will be monitored throughout the study in line with ISO14155 and GCP standards.\n\nThis trial is supported by an unrestricted grant from Medtronic and adheres to ethical guidelines as outlined by the Declaration of Helsinki and GDPR. The REDs study aims to generate clinically relevant evidence to support the integration of RDN into secondary prevention strategies for stroke patients with resistant hypertension.",[30,195,28,196,197,198],"Cerebrovascular Disease","Hypertension","Renal Denervation","Stroke","2025-08-04",{"date":201,"type":50},"2025-08-11",{"date":203,"type":22},"2025-09-25",{"date":205,"type":22},"2029-09-25",{"name":207,"class":57},"Centro per la Lotta Contro l'Infarto - Fondazione Onlus",{"id":209,"slug":210,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":4,"eligibilityCriteria":214,"healthyVolunteers":11,"sex":17,"minAge":215,"maxAge":4,"enrollmentInfo":216,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":217,"conditions":218,"keywords":221,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":4},"100577306","reliability-of-multiple-repetition-maximum-tests-in-patients-with-cardiovascular-disease-or-risk-factors-100577306","NCT06796582","Reliability of Multiple-Repetition-Maximum Tests in Patients with Cardiovascular Disease or Risk Factors","Agreement of the Estimated 1-Repetition-Maximum Between Two Multiple-Repetition-Maximum Tests with Different Weight in Patients with Cardiovascular Disease or Risk Factors","Inclusion Criteria:\n\n* Age ≥ 50 years\n* At least one of the following cardiovascular diseases \u002F risk factors:\n* Heart failure\n* Coronary heart disease\n* Atrial fibrillation\n* Arterial hypertension\n* Type 2 diabetes mellitus\n* Clinically stable for ≥ 4 weeks\n* Medical clearance to perform resistance training \u002F strength testing\n* Signed written informed consent\n\nExclusion Criteria:\n\n* Pregnancy\n* Acute infection\n* Chronic joint inflammation\n* Knee, hip, ankle, wrist, elbow or shoulder pain\n* Known osteoporosis (T-value ≤ -2.5)\n* Uncontrolled hypertension (≥160 mmHG systolic \u002F ≥100 mmHG diastolic)\n* Known cerebral or thoracic aneurysm","50 Years",{"count":129,"type":22},"Exercise training is a cornerstone in the prevention and rehabilitation of cardiovascular disease. While research has primarily focused on endurance training, resistance training becomes more and more important. The gold standard to prescribe resistance training intensity or monitor longitudinal changes is the 1-Repetition-Maximum (1-RM) test. However, particularly for unexperienced individuals, this test may not be recommendable due to the high load and an increased risk of injuries. Alternatively, there are several published formulas to estimate the 1-RM based on a multiple-repetition-maximum (or repetition-to-failure) test. However, these formulas have been primarily tested in healthy individuals. Moreover, the reliability of the 1-RM estimation based on two tests with different submaximal weight is unknown. Therefore, the present study evaluates the agreement of the 1-RM estimation (based on different formulas) between two Multiple-RM tests with different weight in 50 patients with cardiovascular disease (heart failure, coronary heart disease, atrial fibrillation) or cardiovascular risk factors (type 2 diabetes, arterial hypertension).",[73,219,220,74,28],"Coronary Heart Disease (CHD)","Atrial Fibrillation (AF)",[222,223,224,225],"resistance training","cardiovascular disease","cardiovascular risk factors","muscle strength","2025-01-27",{"date":228,"type":50},"2025-01-29",{"date":230,"type":22},"2025-02",{"date":232,"type":22},"2025-06",{"name":234,"class":57},"Technical University of Munich",{"id":236,"slug":237,"hasResults":11,"nctId":238,"briefTitle":239,"officialTitle":239,"acronym":4,"eligibilityCriteria":240,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":241,"targetDuration":242,"studyType":23,"phases":4,"briefSummary":243,"conditions":244,"keywords":4,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":252,"locationsCount":254},"100575206","hypertension-registry-study-of-primary-and-secondary-hypertension-phenotypes-complications-and-treatment-personalization-100575206","NCT06769269","Hypertension Registry: Study of Primary and Secondary Hypertension Phenotypes, Complications, and Treatment Personalization.","Inclusion Criteria:\n\n* Individuals aged over 18 years.\n* Patients with blood pressure:\n\n  * Higher than 140 mmHg systolic and\u002For higher or equal to 90 mmHg diastolic in consultation or in a hospital setting.\n  * Higher than 135\u002F85 mmHg at home or in ambulatory blood pressure measurements (ABPM).\n* Patients who have agreed and signed the informed consent.\n* Patients with legal status in the Moroccan kingdom.\n\nExclusion Criteria:\n\n* Patient without diagnosis of hypertension\n* Patient under 18 years old\n* Patients refusing to sign the informed consent.\n* Patients with illegal status in the kingdom.",{"count":159,"type":22},"1 Year","The quality of primary healthcare systems for patients with hypertension (HTA) in Morocco is a critical issue due to its high prevalence and significant impact on morbidity and mortality. The concept of \"quality in primary care\" encompasses fundamental aspects such as timeliness, accessibility, and the provision of care based on current clinical guidelines and recommendations from professional societies.\n\nThis observational study on hypertension (HTA) uses an electronic registry accessible remotely to collect medical data from primary care and hospital settings. Investigators will be trained to ensure standardization in blood pressure measurements to minimize errors. The registry will include clinical, therapeutic, and complication data for patients aged 18 and over with a confirmed diagnosis of HTA, with information transmitted anonymously via a certified secure channel.\n\nInformed consent from patients will be required for including their data in the registry. Collected data will include anthropometric measurements (weight, height, waist circumference, body mass index), blood pressure measurements by validated devices or ambulatory measurements, and metabolic assessments (blood glucose, total cholesterol, triglycerides, LDL, HDL, urea, creatinine, uric acid, urine albumin-to-creatinine ratio). Cardiovascular complications will also be recorded.\n\nThe study design is a cohort study with a cross-sectional perspective and a targeted follow-up period of one year. The study aims to evaluate the prevalence and phenotypes of HTA in Morocco, as well as the geographic distribution of the disease. It will compare current data with those from previous years and other North African countries to assess the applicability of Moroccan clinical practices and recommendations from the European Society of Cardiology (ESC). The goal is to enhance the understanding and management of HTA, as well as to optimize prevention and treatment strategies.\n\nThis comprehensive analysis will help identify potential gaps in primary care and develop strategies to improve the management of hypertensive patients. The comparative evaluation of data related to examinations, treatments, and complications of the cohort of patients followed for hypertension during the period 2024-2026, in comparison with results from previous years and other countries, will provide valuable insights into the shortcomings and progress in care delivery. This approach will not only identify areas needing improvement but also highlight significant advances in hypertension management.",[28],"2025-01-23",{"date":247,"type":50},"2025-01-24",{"date":249,"type":50},"2025-01-21",{"date":251,"type":22},"2027-01-21",{"name":253,"class":57},"Moroccan Society of Cardiology",5,{"id":256,"slug":257,"hasResults":11,"nctId":258,"briefTitle":259,"officialTitle":260,"acronym":261,"eligibilityCriteria":262,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":263,"enrollmentInfo":264,"targetDuration":4,"studyType":130,"phases":266,"briefSummary":267,"conditions":268,"keywords":4,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":270,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":275,"locationsCount":58},"100571620","telemedical-algorithm-supported-care-for-hypertension-100571620","NCT06722625","Telemedical Algorithm-Supported Care for Hypertension","Telemedical Care System for the Treatment of Arterial Hypertension Using Recommendation Algorithms to Support Diagnostic and Therapeutic Decisions","SOT-ART-HT","Inclusion Criteria:\n\n1. Voluntarily signing an informed consent to participate in the study.\n2. Age between 18 and 80 years.\n3. Diagnosis of hypertension according to the Polish Society of Hypertension criteria from 2019, either already treated or newly diagnosed.\n4. Blood pressure exceeding 140\u002F90 mmHg in office measurements (during the screening visit).\n\nExclusion Criteria:\n\n1. Suspicion or diagnosis of secondary hypertension.\n2. Pregnant women, breastfeeding women, or those planning pregnancy during the study period.","80 Years",{"count":265,"type":22},200,[192],"Hypertension is a major global health issue, affecting around 9 million people in Poland. While some studies indicate that telemonitoring benefits patients with hypertension, there is a lack of research evaluating tools that assist doctors in managing these patients. The objective of this study is to assess a blood pressure monitoring system with an integrated algorithm that aids doctors in the decision-making process.",[28,30],"2024-12-04",{"date":271,"type":50},"2024-12-09",{"date":273,"type":50},"2023-10-01",{"date":54,"type":22},{"name":276,"class":57},"Poznan University of Medical Sciences",{"id":278,"slug":279,"hasResults":11,"nctId":280,"briefTitle":281,"officialTitle":281,"acronym":282,"eligibilityCriteria":283,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":284,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":285,"conditions":286,"keywords":287,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":294,"startDateStruct":296,"completionDateStruct":298,"leadSponsor":300,"locationsCount":58},"100568420","echocardiographic-analysis-by-artificial-intelligence-in-hypertension-100568420","NCT06680986","Echocardiographic Analysis by Artificial Intelligence in Hypertension","CARDINAL","Inclusion Criteria Patients who underwent a comprehensive blood pressure assessment during hospitalization in the Cardiologic Federation at Croix Rousse Hospital and Lyon Sud Hospital between January 2018 and December 2021.\n\nExclusion Criteria Patients who are minors. Patients under curatorship or guardianship.",{"count":265,"type":22},"The objective of this study is to develop artificial intelligence (AI) tools to characterize cardiac remodelling in arterial hypertension through the analysis of routine imaging data (echocardiography) coupled with patient data. More precisely, this study will make it possible (i) to represent in a relevant way the spectrum of the cardiac repercussions of a population affected by hypertension to better characterize the progress of the pathology, in particular vis-à-vis the more ambiguous subjects to be characterized (\"grey\" area); (ii) to develop tools for the automatic quantification of cardiac function (segmentation and robust monitoring of the myocardium during the cardiac cycle, for the dynamic analysis of the shape and global deformation of the heart) and therefore to extract descriptors richer in cardiac function than those currently used in clinical routine.",[28],[196,288,28,289,290,291,292],"HTN","Artificial Intelligence","AI","Cardiac remodelling","Left ventricular hypertrophy","2024-11-07",{"date":295,"type":50},"2024-11-08",{"date":297,"type":50},"2022-06-01",{"date":299,"type":22},"2024-12-31",{"name":301,"class":57},"Hospices Civils de Lyon",{"id":303,"slug":304,"hasResults":11,"nctId":305,"briefTitle":306,"officialTitle":306,"acronym":307,"eligibilityCriteria":308,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":309,"targetDuration":4,"studyType":130,"phases":311,"briefSummary":312,"conditions":313,"keywords":316,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":325,"startDateStruct":327,"completionDateStruct":328,"leadSponsor":330,"locationsCount":58},"100565604","remote-multichannel-monitoring-of-patients-with-chronic-diseases-using-speech-technologies-based-on-artificial-intelligence-100565604","NCT06644339","Remote Multichannel Monitoring of Patients With Chronic DIseAses Using Speech technoLogies Based On Artificial intelliGence","DIALOG","Inclusion Criteria:\n\n* Disease diagnosed according to the latest Clinical practice guidelines\n* Stable condition at the time of discharge from the hospital\n* Written informed consent to participate in the study\n\nNon-inclusion criteria:\n\n* Diagnosed dementia or severe cognitive impairment\n* The inability to use automatic devices to register blood pressure at home, a blood glucose meter\n* Alcohol or drug abuse\n* Inability to contact a voice assistant and other study requirements, due to major co-morbidities, social or financial issues, or a history of noncompliance with medical regimens, that might compromise the patient's ability to understand and\u002For comply with the protocol instructions or follow-up procedures\n\nExclusion Criteria:\n\n* Unwillingness of the patient to continue participating in the study\n* The development of conditions related to the criteria of non-inclusion",{"count":310,"type":22},500,[192],"DIALOG is a study to assess the efficacy and safety of remote patient monitoring using virtual operator voice technologies and a business intelligence (BI) system for timely detection, prevention of early complications, worsening of the condition, and other adverse events in patients who have been discharged from the hospital.",[73,74,28,314,315],"Lymphoproliferative Disease","Total Knee Replacement",[317,84,88,318,319,320,321,322,323],"heart failure","lymphoproliferative diseases","knee replacement","remote monitoring","mHealth","telemedicine","voice assistant","2024-10-15",{"date":326,"type":50},"2024-10-16",{"date":324,"type":22},{"date":329,"type":22},"2025-04-30",{"name":98,"class":57},{"id":332,"slug":333,"hasResults":11,"nctId":334,"briefTitle":335,"officialTitle":335,"acronym":336,"eligibilityCriteria":337,"healthyVolunteers":11,"sex":17,"minAge":338,"maxAge":18,"enrollmentInfo":339,"targetDuration":4,"studyType":130,"phases":341,"briefSummary":342,"conditions":343,"keywords":345,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":348,"lastUpdatePostDateStruct":349,"startDateStruct":351,"completionDateStruct":353,"leadSponsor":355,"locationsCount":4},"100561421","stopping-hypertension-and-improving-childrens-lives-after-kidney-transplantation-100561421","NCT06589947","StOPping Hypertension and imprOving Children's Lives After KidnEy TranSplantation","SOPHOCLES","Inclusion Criteria:\n\n* Kidney transplantation \\>12 months ago\n* Arterial hypertension\n\nExclusion Criteria:\n\n* Cardiac malformation\n* Treatment for a rejection episode within three months prior to inclusion","6 Years",{"count":340,"type":22},170,[192],"Cardiovascular (CV) disease is a major morbidity in children after kidney transplantation (KTx), limiting life expectancy and impairing graft function. Arterial hypertension (AH) is the dominant CV risk factor, and highly abundant in this patient group. AH can cause left ventricular hypertrophy (LVH), which is predictive of CV death. LVH can be non-invasively assessed by measuring left ventricular mass index (LVMI). Analyses of observational data showed that blood pressure (BP) levels \\\u003C75th percentile (pct) were associated with a significant reduction of LVMI. Guidelines give BP goals for children with chronic kidney disease (CKD). No guidelines, however, exist on the treatment of AH in pediatric KTx patients. In the proposed multicenter, randomized, parallel group trial with blinded endpoint evaluation we aim to assess n=500 pediatric patients \\>12 months after KTx at several KTx centers. Patients will be randomly assigned 1:1 to an intensified BP management group (BP target ≤60th pct) and a standard BP management group (BP target \\\u003C90th pct). The primary endpoint is LVMI after 24 months. Secondary endpoints are estimated glomerular filtration rate (eGFR), pulse wave velocity (PWV) and intima media thickness (IMT) after 24 months. BP control will be guaranteed for both groups through BP telemonitoring, which will be transmitted in real time to the treating physician and the trial's centralized BP office. By defining the adequate BP goal, the results of the proposed study will have direct implications for the care of children after KTx. The results will define an important element of post-KTx care and help to lower CV morbidity and subsequently CV mortality of pediatric KTx patients.",[28,344],"Kidney Transplant; Complications",[346,347],"Left ventricular mass","Pediatric kidney transplantation","2024-09-06",{"date":350,"type":50},"2024-09-19",{"date":352,"type":22},"2024-09-16",{"date":354,"type":22},"2029-03",{"name":356,"class":57},"Hannover Medical School",{"id":358,"slug":359,"hasResults":11,"nctId":360,"briefTitle":361,"officialTitle":362,"acronym":4,"eligibilityCriteria":363,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":364,"enrollmentInfo":365,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":367,"conditions":368,"keywords":370,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":377,"lastUpdatePostDateStruct":378,"startDateStruct":379,"completionDateStruct":381,"leadSponsor":383,"locationsCount":58},"100523638","effects-of-change-in-blood-pressure-on-retinal-capillary-rarefaction-in-patients-with-arterial-hypertension-100523638","NCT06098300","Effects of Change in Blood Pressure on Retinal Capillary Rarefaction in Patients With Arterial Hypertension","Effects of Change in Blood Pressure on Retinal Capillary Rarefaction in Patients With Arterial Hypertension - a Pilot Study","Inclusion Criteria:\n\n* Men and Women aged ≥ 18 years\n* Signed informed consent\n* Apart from hypertensive retinopathy, normal ophthalmic findings\n* Non-Smokers\n* Patients with initially diagnosed or pre-existing mild to moderate primary arterial hypertension (systolic office blood pressure ≥ 140 mmHg and\u002For diastolic office blood pressure ≥ 90 mmHg)\n* Planned initiation of antihypertensive medication or planned adaption of antihypertensive medication by the Department of Cardiology\n* Subject agrees to perform regular blood pressure self-measurements and to document blood pressure values in a diary\n\nExclusion Criteria:\n\n* Participation in a clinical trial in the three weeks preceding the study\n* Blood donation in the three weeks preceding the study\n* Symptoms of a clinically relevant illness in the three weeks preceding the study\n* History of family history of epilepsy\n* Secondary hypertension (e.g.: hyperaldosteronism, pheochromocytoma, renal artery stenosis, renal parenchymal diseases, Cushing-syndrome, Coarctatio aortae)\n* History of hypertensive encephalopathy or intracerebral bleeding\n* Diabetes mellitus Type 1 or Type 2\n* Pregnant or breast-feeding women\n* Women of childbearing potential (neither menopausal, nor hysterectomized, nor sterilized) not using effective contraception","90 Years",{"count":366,"type":22},30,"To evaluate whether in patients with initially poorly-controlled arterial hypertension, structural and functional differences in the retina and choroid remain after achieving a well-controlled blood pressure.",[28,369],"Blood Pressure, High",[371,196,372,373,374,375,376],"Retinal Capillary Rarefaction","Antihypertensive medication","OCT-A","Retinal oxygen extraction","Choroidal vascularity index (CVI)","Ocular blood flow","2024-09-05",{"date":350,"type":50},{"date":380,"type":50},"2023-09-01",{"date":382,"type":22},"2025-08",{"name":384,"class":57},"Medical University of Vienna",{"id":386,"slug":387,"hasResults":11,"nctId":388,"briefTitle":389,"officialTitle":390,"acronym":4,"eligibilityCriteria":391,"healthyVolunteers":11,"sex":392,"minAge":215,"maxAge":393,"enrollmentInfo":394,"targetDuration":4,"studyType":130,"phases":396,"briefSummary":397,"conditions":398,"keywords":400,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":406,"lastUpdatePostDateStruct":407,"startDateStruct":409,"completionDateStruct":411,"leadSponsor":413,"locationsCount":58},"100557464","effects-of-resistance-training-intensity-on-cardiovascular-parameters-of-hypertensive-women-100557464","NCT06538454","Effects of Resistance Training Intensity on Cardiovascular Parameters of Hypertensive Women","Acute and Chronic Effects of Resistance Training Intensity on Cardiovascular Parameters of Postmenopausal Women With Systemic Arterial Hypertension","Inclusion Criteria:\n\n* Women with 50 to 65 old years;\n* Postmenopausal diagnosis (amenorrhea for 12 months or more);\n* Previous diagnosis of hypertension and treat with medications;\n* Physically inactive.\n\nExclusion Criteria:\n\n* History of other cardiovascular problems (heart failure, heart attack, stroke, etc);\n* Grade II obesity (BMI ≥ 35 kg\u002Fm²);\n* Medications (beta-blockers and\u002For non-dihydropyridine calcium channel blockers);\n* Systolic blood pressure at rest above 160 mmHg and\u002For dyastolic blood presure above 105 mmHg;\n* Unable to perform resistance exercise due to musculoskeletal or cognitive reasons.","FEMALE","65 Years",{"count":395,"type":22},24,[192],"The goal of this clinical trial is to understand about the effects of resistance training (RT) intensity on cardiovascular parameters in postmenopausal women with systemic arterial hypertension (SAH). The main research questions are:\n\n* Does the intensity of RT impact blood pressure (BP) in postmenopausal women with SAH?\n* How does RT intensity affect heart rate (HR) and their variability (HRV), endothelial function (EF), and nitric oxide (NO) biomarker synthesis in this population?\n* What are the effects of RT intensity on affectivity and rate of perceived exertion (RPE)?\n\nResearchers will compare two different intensities of RT (60% of the load for 1 repetition maximum \\[1RM\\] and 80% of 1RM) to determine their effects on the mentioned cardiovascular and perceptual parameters.\n\nParticipants will:\n\nIn the acute experiment:\n\n* Perform the same RT session in a crossover design, training with 60% of 1RM in one condition and 80% of 1RM in another condition\n* Have BP, HR, and HRV measured before, immediately after, and for one hour post-session\n* Report affectivity before each session and at the end, along with RPE\n\nIn the chronic experiment:\n\n* Be randomized into two groups: one training with 60% of 1RM and the other with 80% of 1RM\n* Undergo a 10-week intervention period with evaluations before, during, and after the intervention\n* Have BP, HR, affective responses, and RPE measured at multiple time points\n* Have EF, HRV, and salivary concentrations of NO biomarkers assessed before and after the intervention",[28,399,30],"Postmenopausal; Menorrhagia",[401,402,403,404,405],"Resistance training","Intensity","Blood pressure","Heart rate variability","Endothelial function","2024-08-01",{"date":408,"type":50},"2024-08-05",{"date":410,"type":50},"2024-07-23",{"date":412,"type":22},"2025-09",{"name":414,"class":57},"University of Sao Paulo",{"id":416,"slug":417,"hasResults":11,"nctId":418,"briefTitle":419,"officialTitle":420,"acronym":421,"eligibilityCriteria":422,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":127,"enrollmentInfo":423,"targetDuration":424,"studyType":23,"phases":4,"briefSummary":425,"conditions":426,"keywords":433,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":435,"lastUpdatePostDateStruct":436,"startDateStruct":437,"completionDateStruct":439,"leadSponsor":441,"locationsCount":444},"100489331","global-research-initiative-for-patients-screening-on-mash-100489331","NCT05651724","Global Research Initiative for Patients Screening on MASH","Global Research Initiative for Patients Screening on MASH - Implementation of an International Transmural Patient Care Pathway","GRIPonMASH","Inclusion Criteria:\n\n* Newly diagnosed subjects should fulfil criteria for diagnosis of type 2 diabetes mellitus or metabolic syndrome or obesity or arterial hypertension, following the study definitions.\n* Subjects that are currently being treated for type 2 diabetes mellitus or metabolic syndrome or obesity or arterial hypertension, should have had a prior diagnosis based on study definitions.\n\nStudy definitions:\n\nType 2 diabetes mellitus\n\n* At least 2 times a fasting glucose \\> 7,0 mmol\u002FL\n* Or elevated non-fasting glucose \\>11,1 mmol\u002FL 2 hrs after OGTT\n* Or HbA1c ≥48 mmol\u002Fmol (≥6.5%)\n* Or being actively treated for previously diagnosed type 2 diabetes by a health care provider\n\nObesity\n\n* Body mass index (BMI) \\> 30\n* Or waist circumferences Caucasian: male ≥ 94 cm, female ≥ 80 cm South-Asian\u002FChinese: male ≥90 cm, female ≥80 cm Japanese: male ≥85 cm, female ≥90 cm\n\nArterial hypertension\n\n* Systolic BP ≥ 140 mmHg and\u002For diastolic BP ≥ 90 mmHg\n* Or being actively treated for previously diagnosed arterial hypertension by a health care provider\n\nMetabolic syndrome\n\n\\- Central obesity defined as waist circumference (see above), if BMI is \\>30 kg\u002Fm2, central obesity can be assumed and waist circumference does not need to be measured\n\nAND any two of the following:\n\n* Raised triglycerides: ≥ 150 mg\u002FdL (1.7 mmol\u002FL), or specific treatment for this lipid abnormality\n* Reduced HDL cholesterol: \\\u003C 40 mg\u002FdL (1.03 mmol\u002FL) in males, \\\u003C 50 mg\u002FdL (1.29 mmol\u002FL) in females, or specific treatment for this lipid abnormality\n* Raised blood pressure (BP): systolic BP ≥ 130 or diastolic BP ≥ 85 mm Hg, or treatment of previously diagnosed hypertension\n* Raised fasting plasma glucose (FPG): FGP ≥ 100 mg\u002FdL (5.6 mmol\u002FL), or previously diagnosed type 2 diabetes (if above \\>5.6 mmol\u002FL or 100 mg\u002FdL, an oral glucose tolerance test is strongly recommended, but is not necessary to define presence of the syndrome)\n\nExclusion Criteria:\n\n* The patient is known with hepatitis B, C or HIV or any other liver condition (like hemochromatosis, sarcoidosis, Wilson's disease etc);\n* The patient is known with any other condition that may lead to liver fibrosis or cirrhosis;\n* The patient engages in (excessive) alcohol use: \\> 3 units\u002Fday in males \\[30 grams\u002Fday\\] and \\> 2 units\u002Fday in females \\[20 grams\u002Fday\\];\n* The patient has a history or evidence of any other clinically significant condition or planned or expected procedure that in the opinion of the Investigator, may compromise the patient's safety or ability to be included in this study;\n* The patient is an employee or contractor of the facility that is conducting the study or is a family member of the Investigator, sub-Investigator, or any Sponsor personnel;\n* The patient is not able to understand the details of the protocol and\u002For is not able to provide written informed consent;\n* The patient is pregnant or breastfeeding.\n* The patient underwent bariatric surgery in the last 12 months.",{"count":159,"type":22},"5 Years","GRIPonMASH will assist (primary) health care providers clinicians to implement the latest patient care pathway, as described by the European Association for the Study of the Liver (EASL), to identify patients at risk of severe metabolic dysfunction-associated steatotic liver disease (MASLD) and to raise awareness. The primary objective is to implement a transmural patient care pathway, in order to identify patients with MASLD and its progressive form metabolic dysfunction-associated steatohepatitis (MASH) in primary care centres and clinics in 10 European countries.",[427,428,429,430,431,432,29,76,28],"MASH","MASLD","MASH With Fibrosis","Fibrosis, Liver","Steatosis of Liver","Type 2 Diabetes",[428,427,79,434],"Patient care pathway","2024-07-30",{"date":406,"type":50},{"date":438,"type":50},"2023-06-30",{"date":440,"type":22},"2031-03-31",{"name":442,"class":443},"Julius Clinical","INDUSTRY",13,{"id":446,"slug":447,"hasResults":11,"nctId":448,"briefTitle":449,"officialTitle":450,"acronym":451,"eligibilityCriteria":452,"healthyVolunteers":11,"sex":392,"minAge":18,"maxAge":453,"enrollmentInfo":454,"targetDuration":4,"studyType":130,"phases":456,"briefSummary":457,"conditions":458,"keywords":459,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":463,"lastUpdatePostDateStruct":464,"startDateStruct":466,"completionDateStruct":468,"leadSponsor":470,"locationsCount":472},"100482538","women-hypertensive-and-young-renal-denervation-100482538","NCT05563337","Women Hypertensive and Young-Renal Denervation","Renal Denervation in Hypertensive Women Planning to Become Pregnant","WHY-RDN","Inclusion Criteria:\n\n* ≥ 18 years and ≤ 40 years\n* Free, informed, written consent signed by the participant and the investigating physician (no later than the day of inclusion and before any examination required by the research)\n* Not pregnant but planning to be pregnant in the near future (\\\u003C2 years)\n* Patient using effective contraception, preferably micro-progestational, during the screening phase and the two-month post-procedure follow-up\n* Essential hypertension confirmed and documented by a previous complete search\n* Hypertension treated by 0-2 antihypertensive treatment(s) in a stable manner for at least 4 weeks and whose clinical BP measured in the sitting position during consultation is ≤ 180\u002F110mmHg at the selection visit (D0),\n* Person able to understand and agree to follow all study procedures\n* Person who is affiliated or beneficiary of a social security plan\n\nNon-Inclusion Criteria:\n\n* Males of any age\n* Females whose age is \\\u003C18 years or \\>40\n* Orthostatic hypotension\n* Hypertension from secondary causes (other than sleep apnea)\n* Documented contraindication or proven severe allergy to iodinated contrast\n* Contraindication to use anticoagulants\n* Renal insufficiency with GFR estimated at \\\u003C 60ml\u002Fmin\u002F1.73m²\n* Antihypertensive treatment with more than two active ingredients\n* Type 1 diabetes or uncontrolled type II diabetes (plasma HbA1c level ≥ 9%)\n* History of chronic inflammatory bowel disease such as Crohn's disease or ulcerative colitis\n* Brachial circumference \\> 40 cm\n* Any history of a cerebrovascular event (stroke, transient ischemic attack)\n* Any history of a serious cardiovascular event (myocardial infarction, acute heart failure requiring hospitalization, coronary artery bypass surgery)\n* Proven and confirmed episodes of stable or unstable angina in the 12 months preceding consent\n* Proven history of persistent or permanent atrial fibrillation\n* Presence of an active implantable medical device (e.g. neuromodulator\u002Fspinal modulator, baroreflex stimulator, ...)\n* Oxygen therapy or permanent ventilation other than CPAP for sleep apnea\n* Primary pulmonary hypertension\n* Limited life expectancy (\\\u003C 1 year)\n* Unresolved history of drug or alcohol abuse\n* Not have sufficient ability to understand or follow instructions\n* In the investigator's opinion she is unlikely to be willing or able to comply with the requirements of the study protocol or participation in the study will involve confounding factors in the analysis of the data\n* Participation in another trial of an investigational drug or device (participation in a non-interventional study is tolerated)\n* Pregnant or nursing mother\n* Person unable to give informed consent\n* Person deprived of liberty by judicial or administrative decision\n* Adults under legal protection\n\nExclusion Criteria:\n\n* BP ≤ 135\u002F85 mmHg and ≥ 160\u002F100 mmHg (ABPM) after 4 weeks washout\u002Frun-in period.\n* Renal arterial anatomy not compatible with renal denervation confirmed by a good quality renal artery angioscan performed within one year prior to consent.\n* Patient without at least one artery on each side that can be treated with 2 or more ablations,\n* Renal artery anatomy:\n\n  * Main renal artery diameter \\\u003C 3.0 mm and \\> 8 mm\n  * Main renal artery length \\\u003C 20 mm\n  * A single functioning kidney (low differentiation or small kidney)\n  * Kidney tumors presence\n  * Renal arterial aneurysm presence\n  * Pre-existing renal stent or history of renal artery angioplasty\n  * Pre-existing aortic stent or history of aortic aneurysm\n  * Prior renal denervation procedure\n  * Fibromuscular dysplasia of the renal arteries\n  * Presence of renal artery stenosis of any origin ≥ 30%\n  * Presence of iliac\u002Ffemoral artery calcification or stenosis precluding insertion of the Paradise Catheter\n  * Infection within 7 days of the procedure","40 Years",{"count":455,"type":22},80,[192],"Renal denervation is a new method to lower blood pressure (BP) in hypertensive patients by reducing the impact of sympathetic nervous system. Its efficacy has been demonstrated in resistant hypertension and in lowering BP in essential hypertension as compared to a sham procedure in untreated hypertensive patients. This procedure is safe without any serious adverse events. However its effects during pregnancy are unknown.\n\nNormal pregnancy is associated with an increase of sympathetic activity at rest and upon cardiovascular reflexes stimulation which returns to baseline after delivery. These changes maintain optimal utero placental blood flow. But excessive stimulation of sympathetic activity may play a role in preeclampsia. Drugs that may affect the sympathetic nervous system are considered as safe in pregnant women.\n\nSo there are reasonable evidence that renal denervation performed before pregnancy should not have deleterious effects for the fetus. The efficiency of renal denervation being greater in young patient and in women, a greater proportion of BP normalization can be expected in this population of young women .",[28],[460,461,462],"Renal denervation","Pregnancy","Arterial hypertension","2023-08-28",{"date":465,"type":50},"2023-08-31",{"date":467,"type":50},"2023-01-31",{"date":469,"type":22},"2028-11-30",{"name":471,"class":57},"University Hospital, Bordeaux",6,{"id":474,"slug":475,"hasResults":11,"nctId":476,"briefTitle":477,"officialTitle":478,"acronym":4,"eligibilityCriteria":479,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":480,"enrollmentInfo":481,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":482,"conditions":483,"keywords":484,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":489,"lastUpdatePostDateStruct":490,"startDateStruct":492,"completionDateStruct":494,"leadSponsor":495,"locationsCount":58},"100513258","fetuin-a-as-a-predictor-of-deterioration-of-renal-function-in-hypertonic-patients-100513258","NCT05963126","Fetuin A as a Predictor of Deterioration of Renal Function in Hypertonic Patients","Modified Urine Fetuin A as a Predictor of Deterioration of Renal Function in Patients With Resistant and Non-resistant Hypertension","Inclusion Criteria:\n\n* Arterial hypertension treated by at least one antihypertensive agent\n\nExclusion Criteria:\n\n* Diabetes mellitus of any type, defined as fasting glucose \\>7,0 mmol\u002Fl or any glycemia \\>11,0 mmol\u002Fl, or HbA1c\\>48 mmol\u002Fmol\n* Decompensated arterial hypertension defined as office blood pressure \\>180\u002F110 mmHg or on Ambulatory Blood Pressure Monitoring (ABPM)\n* Patient with renal replacement therapy\n* Present rheumatoid disease (rheumatoid arthritis, systemic lupus, sclerodermia, dermatomyositis, Inflammatory Bowel Disease, etc.), positivity of antinuclear antibody (ANA) \u002F extractable nuclear antigen (ENA) screening\n* Acute infection defined as C-Reactive Protein (CRP) \\>50 mg\u002Fl\n* Severe impairment of liver function defined as cirrhosis, Alanine Transaminase or ASpartate Transferase (ALT or AST) \\>10 µkat\u002Fl\n* Terminal incurable illness","100 Years",{"count":265,"type":22},"Commonly used parameters (creatinine, estimated glomerular filtration rate, and urine albumin\u002Fcreatinine ratio) for prediction of decline of renal function are sensitive for advanced kidney impairment. Modified human urine Fetuin A (urine Fetuin A) with specific modification in urine (Fetuin A) can earlier predict the progression of kidney disease in patients with diabetes. Studies evaluating urine Fetuin A in hypertonic patients are still lacking.",[28],[28,485,486,487,488],"Resistant Arterial Hypertension","Chronic Kidney Disease","Fetuin A","DNLite IVD103","2023-07-18",{"date":491,"type":50},"2023-07-27",{"date":493,"type":50},"2023-07-01",{"date":54,"type":22},{"name":496,"class":57},"University Hospital Ostrava"]